Lilly/BI's Jardiance Scores A Win In Heart Failure Where Rivals Have Not
A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.
A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.